The Latest Breaking News from FDA

Samsung already has passive AFib detection of irregular heart rhythm. This new patent will use generative AI to convert PPG data into ECG graphs — and we're intrigued.

"There's not enough profit" for drug-makers in life-saving cancer meds, and the FDA can't force them

Amid increasing healthcare spending, breakthroughs in genomics and personalized medicine, and the adoption of new technologies, the pharma industry is booming. So, let’s analyze Eli Lilly (LLY) and Pfizer (PFE) to determine which pharma stock will surge from their first-quarter earnings. Read on to find out.

The pharmaceutical industry is undergoing rapid growth and expansion, driven by rising medical needs, favorable regulatory measures, and the implementation of pharma 4.0. Hence, investors could snatch up quality pharma stocks Bristol-Myers Squibb (BMY), Spero Therapeutics (SPRO), and OptiNose (OPTN) for steady returns during market dips. Read more.

The FDA has just approved the Apple Watch's AFib feature in a watershed moment for digital health tech.

Regulators in the US say the atrial fibrillation history feature can be used to assess other devices.

Pharma companies are slashing insulin production in favour of more lucrative weight-loss drugs.

With rising medicine demand and drug shortages in the U.S., pharmaceutical stocks under $20 present lucrative opportunities for investors, promising substantial returns in a ripe market. So, I think fundamentally solid pharma stocks ACADIA Pharmaceuticals (ACAD), Amneal Pharmaceuticals (AMRX), and OptiNose (OPTN), which are currently trading under $20, could be…

The Department of Medical Sciences has warned against overconsumption of kratom-mixed beverages, saying the drink may contain a higher level of mitragynine than the Food and Drug Administration's (FDA) recommendation.

FDA testing confirms safety of dairy products in the US market, offering reassurance to consumers amid bird flu concerns.

For some conditions, few approved treatments exist. Without accelerated approval, the FDA is failing patients